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ABSTRACT
Introduction: The glucagon-like peptide-1
(GLP-1) receptor agonist class has grown in the
last decade, with several agents available in the
UK. However there is currently a paucity of
evidence regarding the relative
cost-effectiveness of liraglutide 1.2 mg versus
other daily administered GLP-1 receptor
agonists, due to a lack of head-to-head trial
data. Therefore the present analysis was
performed, using results from a network
meta-analysis (NMA), to compare the
cost-effectiveness of three currently available
daily administered GLP-1 receptor agonists for
treatment of diabetes in the UK setting.
Methods: A validated and published diabetes
model was used to make long-term projections
of clinical outcomes and direct costs (2015
GBP) for patients receiving liraglutide 1.2 mg
once-daily, exenatide 10 lg twice daily and
lixisenatide 20 lg once-daily. Treatment effects
were taken from an NMA evaluating the
efficacy of GLP-1 receptor agonists and were
applied in a cohort based on the Liraglutide
Effect and Action in Diabetes 6 (LEAD-6) trial.
Costs and utilities were based on published
sources.
Results: Liraglutide 1.2 mg was associated with
improved quality-adjusted life expectancy
versus exenatide [9.19 versus 9.17
quality-adjusted life years (QALYs)] and
lixisenatide (9.19 versus 9.12 QALYs).
Improvements were driven by benefits in
glycemic control, leading to a reduced
incidence of diabetes-related complications.
Liraglutide 1.2 mg was associated with reduced
costs versus exenatide (GBP 36,394 versus
GBP 36,547) and lixisenatide (GBP 36,394
versus GBP 36,496), with cost savings as a
result of complications avoided entirely
offsetting increased acquisition costs. Based on
the projected outcomes, liraglutide was found
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to be dominant over both exenatide and
lixisenatide.
Conclusion: Liraglutide 1.2 mg is likely to be
considered cost-effective versus alternative daily
administered GLP-1 receptor agonists for
treatment of type 2 diabetes in the UK.
Keywords: Cost; Cost-effectiveness; Diabetes
mellitus; Exenatide; GLP-1 receptor agonist;
Liraglutide; Lixisenatide
INTRODUCTION
Type 2 diabetes mellitus is a complex and
progressive disease that is associated with a
significant clinical and economic burden
globally. Currently 415 million people have
diabetes worldwide, with type 2 diabetes
representing approximately 90% of cases, and
it is estimated that this will rise to 642 million
in 2040 [1]. In the United Kingdom (UK) the
prevalence of diabetes is 6.2%, with 3.3 million
diagnosed patients [2]. In 2013, over 50,000
hospital admissions and approximately 5000
deaths were attributable to the disease. Across
the UK, one in seven hospital beds is occupied
by a patient with diabetes, and in some
hospitals this can be as high as 30% of beds
[3]. People with diabetes are at twice the risk of
experiencing a cardiovascular event during
their lifetime compared with the general
population, and diabetes is the most common
cause of renal failure (the primary cause in over
25% of patients) [4, 5]. The risk of micro- and
macrovascular complications can be reduced
through maintaining glycemic control and
managing other risk factors such as body
weight, hypertension and hyperlipidemia [6–8].
Diabetes is also associated with a significant
economic burden in the UK, with type 2
diabetes comprising the majority of this. In
2011 the annual direct cost of type 2 diabetes
was estimated to be GBP 8.8 billion, with
indirect costs of GBP 13 billion. It is projected
that direct and indirect costs will increase to
GBP 15.1 billion and GBP 20.5 billion,
respectively, by 2035 [9]. It has been estimated
that drug costs make up less than 10% of the
total cost burden of diabetes in the UK and that
the predominant driver of the economic burden
is diabetes-related complications [9].
The glucagon-like peptide-1 (GLP-1) receptor
agonist class represents an attractive treatment
option for patients with type 2 diabetes and their
use has grown in the last decade. Within the UK,
three alternative daily administered GLP-1
receptor agonists are available: exenatide 10 lg
twice daily (BID, approved by the European
Medicines Agency in 2006), liraglutide 1.2 or
1.8 mg once daily (approved in 2009) and
lixisenatide 20 lg once daily (approved in 2013).
The GLP-1 receptor agonists act through
activation of the GLP-1 receptor, which is
present within a number of tissues, resulting in
a range of physiological effects. These include
stimulation of glucose-dependent insulin
secretion, inhibition of glucagon release,
delaying gastric emptying, and increasing satiety
[10, 11]. This broad mechanism of action gives
the GLP-1 receptor agonists a number of favorable
treatment characteristics. As well as improved
glycemic control, GLP-1 receptor agonists are
associated with weight loss, reductions in blood
pressure, and low risk of hypoglycemia [10, 11].
This has been shown to result in long-term
benefits, with data from the randomized,
double-blinded Liraglutide Effect and Action in
Diabetes: Evaluation of Cardiovascular Outcome
Results (LEADER) trial (NCT01179048) showing
that liraglutide 1.8 mg was associated with
statistically significant reductions in the risk of
cardiovascular disease, death from any cause, and
nephropathy compared with placebo over a
median of 3.8 years of follow-up, and a
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retrospective analysis of 39,275 patients has also
suggested that exenatide may be associated with a
reduced risk of cardiovascular events than other
treatment options [12, 13].
While numerous studies have been
conducted that have compared GLP-1 receptor
agonists with other therapy options such as
sulfonylureas, thiazolidinediones, dipeptidyl
peptidase 4 inhibitors, and insulin glargine,
only three published studies have directly
compared daily administered GLP-1 receptor
agonists for a period greater than 24 weeks
[14–22]. The Liraglutide Effect and Action in
Diabetes 6 (LEAD-6) trial (NCT00518882)
compared liraglutide 1.8 mg with exenatide
10 lg BID in patients with type 2 diabetes
failing to achieve glycemic targets on
metformin and/or sulfonylurea [20].
Liraglutide 1.8 mg reduced mean glycated
hemoglobin (HbA1c) significantly more than
exenatide 10 lg BID (estimated treatment
difference -0.33; 95% confidence interval
-0.47 to -0.18; p\0.0001), and more patients
receiving liraglutide achieved an HbA1c target
of \7% (54% versus 43%, respectively). Both
liraglutide 1.8 mg and exenatide 10 lg BID were
associated with similar weight loss (-3.24 and
-2.87 kg, respectively). Rates of hypoglycemia
were low in both treatment arms, but liraglutide
1.8 mg was associated with a statistically
significant reduction in minor hypoglycemic
events (1.93 versus 2.60 events per patient per
year; p = 0.0131).
Liraglutide 1.8 mg and lixisenatide 20 lg
were compared in patients with type 2
diabetes not meeting glycemic targets on
metformin monotherapy in the LIRA-LIXI trial
(NCT01973231) [22]. Liraglutide 1.8 mg was
associated with a greater reduction in HbA1c
(estimated treatment difference -0.62%; 95%
confidence interval -0.80% to -0.44%;
p\0.0001) and greater proportions of patients
achieving HbA1c targets of \7% and B6.5%.
Both interventions were associated with similar
reductions in blood pressure and body weight,
and had similar safety profiles.
The GetGoal-X study (NCT00707031)
compared lixisenatide 20 lg with exenatide
10 lg BID in patients with type 2 diabetes failing
to achieve glycemic control on metformin
monotherapy [21]. The two therapies were
found to be comparable, with lixisenatide 20 lg
found tobenon-inferior to exenatide 10 lgBID in
termsof reduction inHbA1c (estimated treatment
difference 0.17%; 95% confidence interval 0.033
to 0.297%) and similar proportions of patients
achieved an HbA1c target of\7% (48.5% with
lixisenatide and 49.8% with exenatide). Weight
loss was also similar with lixisenatide 20 lg and
exenatide 10 lg BID (-2.96 kg with lixisenatide
and -3.98 kg with exenatide). No patients in
either treatment arm experienced a severe
hypoglycemic event, but a lower proportion of
patients experienced non-severe events with
lixisenatide 20 lg (2.5%) than with exenatide
10 lg (7.9%).
Whilst there are clinical trials comparing
liraglutide 1.8 mg with other daily administered
GLP-1 receptor agonists, to date, there is a
paucity of head-to-head trial evidence for
liraglutide 1.2 mg versus other daily
administered GLP-1 receptor agonists.
Recently, a network meta-analysis comparing
the efficacy and safety of daily administered
GLP-1 receptor agonists for the treatment of
insulin naı¨ve patients with type 2 diabetes has
been published [23]. This network meta-analysis
based on 13 randomized, controlled trials
represents the first assessment of the relative
efficacy of currently available daily
administered GLP-1 receptor agonists with
liraglutide 1.2 mg included.
The healthcare budget within the UK is
coming under increased pressure, with an
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ageing population and limited increases in
healthcare spending planned over the coming
years. The aim of health economic evaluation is
to ensure efficient allocation of resources such
that the National Health Service (NHS) achieves
the maximum healthcare gains across the
population within the restrictions of the limited
budget. A number of health economic
evaluations comparing GLP-1 receptor agonists
with other classes of therapy have been published
[24–27]. However, to date, only one long-term
modeling analysis assessing the cost-effectiveness
of alternative daily administered GLP-1 receptor
agonists in the UK setting has been conducted.
This analysis assessed the cost-effectiveness of
liraglutide 1.8 mg and exenatide 10 lg BID in the
UK setting based on the LEAD-6 study, and
concluded that liraglutide 1.8 mg was
cost-effective [28]. The cost-effectiveness of
liraglutide 1.2 mg once daily has not been
assessed versus either exenatide 10 lg BID or
lixisenatide 20 lg once-daily, reflecting the lack of
head-to-head trial evidence for liraglutide 1.2 mg
versus other GLP-1 receptor agonists.
The aim of the present analysis was to explore
this area further and to compare the long-term
cost-effectiveness of currently available daily
administered GLP-1 receptor agonists for which
there is no head-to-head trial evidence. The study
evaluated the cost-effectiveness of liraglutide
1.2 mg, exenatide 10 lg BID and lixisenatide
20 lg, for treatment of patients with type 2
diabetes in the UK setting based on the results
of a network meta-analysis [23].
METHODS
Model Description
The analysis was performed using the IMS CORE
Diabetes Model (IMS Health, Basel,
Switzerland), the architecture, assumptions,
features and capabilities of which have been
previously published [29]. The model is a
validated, non-product specific diabetes policy
analysis tool and is based on a series of
inter-dependent sub-models that simulate the
complications of diabetes (angina, myocardial
infarction, congestive heart failure, stroke,
peripheral vascular disease, diabetic
retinopathy, macular edema, cataract,
hypoglycemia, ketoacidosis, lactic acidosis,
nephropathy and end-stage renal disease,
neuropathy, foot ulcer and amputation, and
non-specific mortality). Each sub-model has a
semi-Markov structure and uses time, state,
time-in-state and diabetes type-dependent
probabilities derived from published sources
(full details available from Palmer et al. 2004
[29]). Monte Carlo simulation using tracker
variables overcomes the memory-less
properties of the standard Markov model, and
allows interconnectivity and interaction
between individual complication sub-models.
Long-term outcomes projected by the model
have been validated against real life data in
2004 and more recently in 2014 [30, 31].
A simulated cohort of 1000 patients was run
through the model 1000 times for each
simulation (base case and sensitivity analyses).
Mean values and standard deviations were
generated for long-term outcomes (life
expectancy, quality-adjusted life expectancy,
cumulative incidence of diabetes-related
complications, time to onset of
diabetes-related complications, direct medical
costs). The time horizon was set to patient
lifetimes in the base case (50 years) to capture
all relevant long-term complications and
associated costs, thereby assessing their impact
on life expectancy and quality-adjusted life
expectancy. Future costs and clinical benefits
were discounted symmetrically by 3.5% per
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annum in line with published health economic
guidance for the UK [32].
Simulated Cohort
The baseline cohort of the analysis was based on
the LEAD-6 trial, a 26-week, open-label,
parallel-group study comparing liraglutide
1.8 mg once daily with exenatide 10 lg BID [20].
Participants were eligible to take part if they had
type 2 diabetes with HbA1c of 7–11%, were aged
18–80 years, with body mass index (BMI) of
45.0 kg/m2 or less, and were on stable treatment
with metformin and/or sulfonylurea. Exclusion
criteria were previous treatment with insulin,
previous treatment with exenatide or liraglutide,
impaired liver or renal function, clinically
significant cardiovascular disease, retinopathy or
maculopathy requiring acute treatment,
uncontrolled hypertension (C180/100mmHg),
or cancer. The mean age of the cohort was
56.7 years (standard deviation 10.3 years), with a
mean HbA1c of 8.2% (standard deviation 1.0%)
and a mean duration of diabetes of 8.2 years
(standard deviation 6.0 years). This cohort was
chosen as it is likely to represent patients that are
receiving GLP-1 receptor agonists in clinical
practice in the UK. The IMS CORE Diabetes
generates the cohort to be applied in the
modeling analysis based on the LEAD-6 data by
sampling around the mean values based on
standard deviations for each parameter.
Estimation of Treatment Effects
The study aimed to assess the cost-effectiveness
of daily administered GLP-1 receptor agonists
where there is currently no head-to-head trial
evidence (liraglutide 1.2 mg, exenatide 10 lg
BID and lixisenatide 20 lg). Clinical data were
taken, therefore, from a network meta-analysis
of 13 randomized, controlled trials evaluating
the efficacy and safety of daily administered
GLP-1 receptor agonists for the treatment of
insulin naı¨ve patients with type 2 diabetes [23].
Change from baseline in HbA1c, BMI and
systolic blood pressure were taken from the
network meta-analysis. For each of the
therapies, the network meta-analysis provided
the mean differences in each parameter, versus
each of the other therapies. Therefore to
calculate the treatment effects to be applied in
the modeling analysis, these differences were
applied to a reference treatment. Treatment
differences versus liraglutide 1.8 mg identified
in the network meta-analysis (Table 1) were
applied to the liraglutide 1.8 mg arm of the
LEAD-6 study to give the treatment effects
applied in the first year of the analysis in each
of the treatment arms (Table 2). No data were
available to inform the systolic blood pressure
change in the lixisenatide 20 lg arm and
therefore this was matched to the liraglutide
1.2 mg arm. This is likely to be a conservative
approach as liraglutide 1.2 mg was associated
with a greater reduction in systolic blood
pressure than exenatide 10 lg BID, and
therefore in the absence of data for
lixisenatide 20 lg the most favourable change
was assumed. Moreover, it is likely that the
alternative GLP-1 receptor agonists are
associated with comparable reductions in
systolic blood pressure [33, 34]. Liraglutide
1.2 mg was associated with a statistically
significant reduction in HbA1c compared to
exenatide 10 lg BID and lixisenatide 20 lg, but
differences in systolic blood pressure and BMI
were not statistically significant.
Treatment Intensification and Long-term
Parameter Progression
Patients were assumed to receive GLP-1 receptor
agonist therapy for 3 years before intensifying
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to receive neutral protamine Hagedorn (NPH)
insulin for the remainder of the simulation.
This assumption recognizes that intensification
to basal insulin will be required to maintain
glycemic control, and is in line with previously
published cost-effectiveness analyses and
submissions to the National Institute for
Health and Care Excellence (NICE) [24, 35].
Alternative assumptions around treatment
switching were tested in sensitivity analyses
(see below). Following application of the
treatment effects in the first year of the
analysis, HbA1c and systolic blood pressure
were assumed to follow the natural
progression algorithms built into the IMS
CORE Diabetes Model, based on the United
Kingdom Prospective Diabetes Study (UKPDS)
[29]. BMI was assumed to remain constant
whilst patients received GLP-1 receptor agonist
therapy, and returned to baseline on
intensification to NPH insulin.
Costs and Utilities
Costs were accounted from an NHS healthcare
payer perspective in the UK in 2015 pounds
sterling (GBP). Costs of therapy captured the
respective GLP-1 receptor agonists,
concomitant metformin, needles and
self-monitoring of blood glucose testing (three
Table 1 Outcomes of the network meta-analysis used in the modeling analysis
Liraglutide 1.2 mg Exenatide 10 lg BID Lixisenatide 20 lg
Mean difference in change from
baseline HbA1c versus
liraglutide 1.8 mg (%)
?0.10 (-0.22 to ?0.03) ?0.32 (?0.15 to ?0.78) ?0.54 (?0.33 to ?0.75)
Mean difference in change from
baseline systolic blood pressure
versus liraglutide 1.8 mg (mmHg)
?0.15 (-2.27 to ?2.49) ?0.52 (-4.69 to ?5.75) No data
Mean difference in change from
baseline BMI versus
liraglutide 1.8 mg (kg/m2)
?0.30 (-0.17 to ?0.76) -0.22 (-0.76 to ?0.30) ?0.18 (-0.56 to ?0.93)
Positive values indicated that the therapy is associated with a smaller reduction in the endpoint compared to liraglutide
1.8 mg. Values in brackets represent 95% conﬁdence intervals
BID bis in die, BMI body mass index, HbA1c glycated hemoglobin
Table 2 Treatment effects applied in the ﬁrst year of the modeling analysis
Liraglutide 1.2 mg Exenatide 10 lg BID Lixisenatide 20 lg
Change from baseline HbA1c (%) -1.02 -0.80* -0.58*
Change from baseline systolic blood pressure (mmHg) -2.36 -1.99 -2.36
Change from baseline BMI (kg/m2) -0.85 -1.37 -0.97
BID bis in die, BMI body mass index, HbA1c glycated hemoglobin
* Statistically signiﬁcant difference when compared to the liraglutide 1.2 mg arm
 No data so conservatively assumed equal to the liraglutide 1.2 mg arm
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tests per week in all treatment arms). Costs of
treating diabetes-related complications
(Table 3) were identified through literature
review, with costs inflated to 2015 values
using the Hospital and Community Health
Services price index were necessary [36].
Health-related quality of life utilities associated
with diabetes-related complications were
derived from previous cost-effectiveness
evaluations of GLP-1 receptor agonists carried
out in the UK setting (Table 4) [24, 25].
Sensitivity Analyses
A number of sensitivity analyses were
conducted to identify key drivers of outcomes
in the base case analysis. The influence of time
horizon on the model outcomes was assessed by
running the analyses over 20 years. It should be
noted that this analysis does not capture all
long-term outcomes, as not all patients were
dead at the end of the simulation. The effect of
discount rates on future costs and clinical
outcomes was investigated through analyses in
which they were set (symmetrically) to 0% and
6% per annum, in line with guidance for the UK
setting [32]. The key drivers of clinical outcomes
were assessed by abolishing the differences in
individual clinical parameters between the
liraglutide 1.2 mg arm and the comparator
arms. Additional analyses with only the
statistically significant differences between
liraglutide 1.2 mg and each of the two
comparators applied were conducted. The
influence of treatment switching was assessed
in analyses with treatment switching pushed
back to 5 years in all treatment arms, and
triggered by patients exceeding an HbA1c
threshold of 8.0% (resulting in treatment
switching in different years for the alternative
GLP-1 receptor agonists). Analyses were also
conducted where patients switched to insulin
glargine, rather than NPH insulin, after 3 and
5 years of GLP-1 receptor agonist therapy. An
alternative set of cost of complications data
were applied, based on the NICE liraglutide
submission, with all values inflated to 2015 GBP
[32, 36]. In February 2014, an update to the IMS
CORE Diabetes Model incorporating data from
the UKPDS 82 was released, and an analysis
using this version of the model has been run for
each comparison [37]. Whilst a validation study
of the revised model has been published, the
model proprietors suggest that the update is
used in a sensitivity analysis, with the previous
version being used in the base case. An analysis
was conducted with clinical and cost outcomes
projected for liraglutide 1.34 mg, as this reflects
the mean dose of liraglutide received in the UK,
based on a review of prescription data [38].
Compliance with Ethics Guidelines
This article does not contain any new studies
with human or animal subjects performed by
any of the authors.
RESULTS
Base Case Analysis
The base case analysis found that liraglutide
1.2 mg was associated with benefits in life
expectancy and quality-adjusted life
expectancy versus other daily administered
GLP-1 receptor agonists, at 13.73 years and
9.19 quality-adjusted life years (QALYs),
respectively (Table 5). Lixisenatide 20 lg was
associated with the lowest life expectancy
(13.67 years) and quality-adjusted life
expectancy (9.12 QALYs). Differences between
the three therapy arms resulted from differences
in the cumulative incidence of end-stage
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diabetes-related complications, driven by
differences in glycemic control. Liraglutide
1.2 mg was associated with the lowest
cumulative incidence of microvascular and
macrovascular diabetes-related complications,
followed by exenatide 10 lg BID, followed by
lixisenatide 20 lg (Fig. 1). The mean time to
onset of complications also differed between
the treatment arms. Time free of all
complications with liraglutide 1.2 mg was
increased by 0.1 years versus exenatide 10 lg
BID (4.8 years) and 0.3 years versus lixisenatide
20 lg (4.6 years). The largest benefit with
liraglutide 1.2 mg was seen in the delayed
onset of neuropathy, delayed by 0.2 years
compared with exenatide 10 lg BID and
0.3 years compared with lixisenatide 20 lg.
Exenatide 10 lg BID was associated with the
highest mean direct costs over patient lifetimes
(Fig. 2) at GBP 36,547, followed by lixisenatide
20 lg (GBP 36,496) and liraglutide 1.2 mg
(GBP 36,394). The analysis found that
liraglutide 1.2 mg was associated with the
highest treatment costs, due to the higher
acquisition costs of the medication over the
first three years of the analysis. However,
liraglutide 1.2 mg was associated with the
lowest costs of treatment of diabetes-related
complications (GBP 27,337 versus GBP 27,712
with exenatide 10 lg BID and GBP 28,023 with
lixisenatide 20 lg). This resulted in liraglutide
1.2 mg being associated with cost savings of
GBP 153 versus exenatide 10 lg BID and
GBP 103 versus lixisenatide 20 lg, as costs
savings as a result of avoided diabetes-related
complications entirely offset the increased
treatment costs.
Liraglutide 1.2 mg was associated with
improved clinical outcomes at a cost saving
versus exenatide 10 lg BID and lixisenatide










Angina, year of onset 2891 [42]
Angina, years 2? 1935 [43]
Congestive heart failure, year
of onset
2702 [44]
Congestive heart failure, years
2?
587 [44]
Stroke, year of event 9441 [44]
Stroke, years 2? 2538 [44]







Hemodialysis, onset 41,179 [47]
Hemodialysis, years 2? 41,179 [47]
Peritoneal dialysis, onset 22,646 [47]
Peritoneal dialysis, years 2? 22,646 [47]
Kidney transplant, ﬁrst year 24,334 [47]
Kidney transplant, years 2? 7908 [47]
Laser treatment 136 [46]
Cataract operation 858 [46]
Cataract operation, years 2? 502 [48]
Blindness, ﬁrst year 5567 [49]
Blindness, years 2? 5567 [49]
Neuropathy, year of onset 968 [46]
Neuropathy, years 2? 968 [46]
Amputation, procedure 9820 [46]
Amputation, prosthesis 2052 [50]
Gangrene treatment 41,420 [50]
Cost after healed ulcer 261 [50]
Infected foot ulcer 23,748 [50]
Uninfected foot ulcer 23,282 [50]
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20 lg. Therefore liraglutide 1.2 mg was
considered dominant over both alternative
daily administered GLP-1 receptor agonists.
Sensitivity Analyses
Sensitivity analyses identified that the key
driver of improved clinical outcomes with
liraglutide 1.2 mg was a greater reduction in
HbA1c than with exenatide 10 lg BID and
lixisenatide 20 lg (Table 6). Abolishing the
HbA1c difference versus each of the two
alternative GLP-1 receptor agonists resulted in
reduced life expectancy and increased direct
costs for liraglutide 1.2 mg versus exenatide
10 lg BID and lixisenatide 20 lg. Abolishing
the systolic blood pressure benefit (only
possible in the comparison with exenatide
10 lg BID) showed that this also drove an
improvement in clinical outcomes with
liraglutide 1.2 mg, but the effect was not as
large as for HbA1c. Applying only the
statistically significant difference of HbA1c in
each comparison (with all other inputs set to
the value in the comparator arm) did not
change the conclusion that liraglutide 1.2 mg
was dominant over exenatide 10 lg BID and
lixisenatide 20 lg.
Reducing the time horizon to 20 years
resulted in reduced quality-adjusted life
expectancy and direct costs in all three
treatment arms. While liraglutide 1.2 mg
remained dominant versus exenatide 10 lg
BID and lixisenatide 20 lg, increases in
quality-adjusted life expectancy and cost
savings were not as large as in the base case
analysis. This reflects the long-term benefits of
improved glycemic control during treatment
with liraglutide 1.2 mg. Altering the discount
rates also reflected the long-term benefits
Table 4 Utilities applied in the modeling analysis
Complication Utility References
Diabetes, no complications 0.814 [51]
Myocardial infarction, year of
event
–0.129 [51]
Myocardial infarction, years 2? 0.736 [51]
Angina 0.682 [51]
Congestive heart failure 0.633 [51]
Stroke, year of the event –0.181 [51]
Stroke, years 2? 0.545 [51]
Peripheral vascular disease 0.57 [52]
Microalbuminuria 0.814 [51]
Gross proteinuria 0.814 [51]
Hemodialysis 0.490 [52]
Peritoneal dialysis 0.560 [52]
Renal transplant 0.762 [52]








Macular edema 0.794 [29]
Severe vision loss 0.734 [51]
Cataract 0.794 [51]
Neuropathy 0.624 [29]
Healed ulcer 0.814 [51]
Active ulcer 0.600 [29]
Amputation, year of event -0.109 [51]
Amputation, years 2? 0.680 [51]
Severe hypoglycemia -0.0565 [53]
Non-severe hypoglycemia -0.0041 [53]
Each unit of body mass index over
25 kg/m2
-0.0061 [54]
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associated with liraglutide 1.2 mg. Applying a
discount rate of 0% resulted in an increased
clinical benefit and increased cost savings over
exenatide 10 lg BID and lixisenatide 20 lg.
Clinical outcomes were stable when
alternative assumptions around treatment
switching were evaluated, but cost outcomes
were sensitive to changes. Assuming that
patients receiving insulin glargine rather than
NPH insulin resulted in only minor changes in
the incremental cost outcomes, and the
conclusions of the analyses did not change.
Assuming patients received GLP-1 receptor
agonist therapy for 5 years before switching to
NPH insulin resulted in increased costs in the
liraglutide 1.2 mg arm compared with both
exenatide 10 lg BID and lixisenatide 20 lg,
with ICERs of GBP 1939 and GBP 3693 per
QALY gained respectively. When patients
received insulin glargine, rather than NPH
insulin, after 5 years of GLP-1 receptor agonist
therapy ICERs were increased to GBP 2195 and
GBP 3854 per QALY gained versus exenatide
10 lg BID and lixisenatide 20 lg, respectively.
Use of an HbA1c threshold of 8.0% to trigger
treatment intensification resulted in treatment
switching occurring in year 3 with lixisenatide
20 lg, and year 4 with liraglutide 1.2 mg and
exenatide 10 lg BID. Liraglutide 1.2 mg was
associated with smaller cost savings versus
exenatide 10 lg BID, and increased costs of
GBP 523 versus lixisenatide 20 lg. Differences
in total direct costs in these scenarios were
driven predominantly by changes in the cost of
acquiring the GLP-1 receptor agonists due to the
variation in duration of therapy.




















20.77 (0.32) 20.75 (0.32) 20.66 (0.34) ?0.02 ?0.11
Discounted life expectancy (years) 13.73 (0.16) 13.71 (0.17) 13.67 (0.18) ?0.02 ?0.06
Discounted quality-adjusted life
expectancy (QALYs)
9.19 (0.11) 9.17 (0.11) 9.12 (0.12) ?0.02 ?0.07
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Applying an alternative set of cost of
complications data resulted in lower direct
costs in all three treatment arms. The higher
acquisition cost of liraglutide 1.2 mg remained
completely offset by cost savings as a resulted of
avoided complications in the comparison with
exenatide 10 lg BID, but increased costs were
only partially offset in the comparison with
lixisenatide 20 lg. An ICER of GBP 2458 per
QALY gained was calculated for liraglutide
1.2 mg versus lixisenatide 20 lg.
Using the updated UKPDS risk equations to
calculate the risk of clinical events resulted in
increased quality-adjusted life expectancy in all
treatment arms, but differences between the
treatment arms remained similar. Costs were
reduced with all therapies. Liraglutide 1.2 mg
and exenatide 10 lg BID were associated with
comparable costs, and liraglutide 1.2 mg was
associated with increased costs of GBP 146
versus lixisenatide 20 lg.
Analysis of liraglutide 1.34 mg, reflecting the
mean dose received in clinical practice in the
UK, resulted in ICERs of GBP 5120 and
GBP 2513 per QALY gained versus exenatide
10 lg BID and lixisenatide 20 lg, respectively
[38]. This reflected the increased clinical benefit
and the increased cost of the higher dose.
DISCUSSION
The present analysis found that treatment with
liraglutide 1.2 mg once daily was associated
with improved long-term clinical outcomes
versus exenatide 10 lg BID and lixisenatide
20 lg once daily in the UK. The network
meta-analysis on which the analysis was based
identified that liraglutide 1.2 mg was associated
with a greater reductions in HbA1c and systolic
blood pressure than exenatide 10 lg BID and
lixisenatide 20 lg [23]. These improvements
drove greater reductions in the cumulative
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Fig. 1 Cumulative incidence of diabetes-related complica-








































Fig. 2 Direct costs in each of the treatment arms. BID bis
in die, GBP 2015 pounds sterling
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increased the time to onset of diabetes-related
complications, and resulted in increased life
expectancy and quality-adjusted life expectancy
in long-term projections. Liraglutide 1.2 mg was
associated with higher acquisition costs, but
lower costs of treating diabetes-related
complications. This resulted in liraglutide
1.2 mg being associated with reduced overall
direct costs versus exenatide 10 lg BID and
lixisenatide 20 lg, with liraglutide 1.2 mg found
to be dominant over exenatide 10 lg BID and
lixisenatide 20 lg. Therefore liraglutide 1.2 mg
is likely to be considered a cost-effective
treatment option for patients with type 2
diabetes in the UK setting, compared with
alternative daily administered GLP-1 receptor
agonists.
Metformin remains the first-line
pharmacological therapy for patients with type
2 diabetes in the UK. Clinicians have a number
of treatment options for a second agent to be
added to metformin, and a previous analysis has
assessed the cost-effectiveness of liraglutide
versus sulfonylureas and dipeptidyl peptidase 4
(DPP-4) inhibitors in the UK setting [24]. This
analysis found that liraglutide 1.2 mg was
cost-effective versus both comparators, but the
key drivers of the improved clinical outcomes
varied (greater reductions in systolic blood
pressure and BMI versus sulfonylurea and
greater reductions in HbA1c and BMI versus
DPP-4 inhibitors). Given the multifactorial
clinical benefits of daily administered GLP-1
receptor agonists (liraglutide, exenatide BID and
lixisenatide) and their potential to address
many of the clinical needs of patients with
type 2 diabetes, the present analysis sought to
address the question of which of these agents is
most cost-effective. The present analysis is the
first to evaluate the cost-effectiveness of daily
administered GLP-1 receptor agonists available
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liraglutide 1.2 mg may be the most
cost-effective daily administered GLP-1
receptor agonist.
In the UK, GLP-1 receptor agonists are
recommended for patients with type 2
diabetes who have a BMI of 35 kg/m2 or
higher and specific psychological or other
medical problems associated with obesity, or
patients who have a BMI lower than 35 kg/m2
and for whom insulin therapy would have
significant occupational implications or weight
loss would benefit other significant
obesity-related comorbidities. The present
analysis aimed to explore the cost-effectiveness
of liraglutide 1.2 mg versus other once daily
administered GLP-1 receptor agonists where
there is no head-to-head trial evidence. The
analysis did not include liraglutide 1.8 mg, as
there are studies available to directly to compare
cost-effectiveness with exenatide 10 lg BID and
lixisenatide 20 lg [20, 22]. A potential
limitation of the study may be the use of a
network meta-analysis to inform the clinical
parameters of the modeling analysis. In the
absence of head-to-head data, the network
meta-analysis represents the best available
source of evidence to compare the three daily
administered GLP-1 receptor agonists. The use
of evidence synthesis is becoming more widely
accepted as part of economic evaluation of new
interventions, and guidelines on best practice
methods are available, with particular relevance
to the UK setting [23, 39]. However, a number
of the comparisons included in the network
meta-analysis were represented by only one trial
and this limited data pool may increase
uncertainty around the outcomes.
Furthermore, a number of the studies included
in the network meta-analysis were open-label
due to the nature of comparing an
injectable agent with an oral agent, or
comparing injectable agents with different
injection frequencies. Additionally, the
network meta-analysis did not provide all
inputs required for an analysis using the IMS
CORE Diabetes Model. For example, the
network meta-analysis calculated the
proportion of patients experiencing
hypoglycemic events rather than rates of
hypoglycemic events (which may affect
quality of life) as required by the IMS CORE
Diabetes Model, and no data were provided on
changes in serum lipids (which may drive
differences in cardiovascular outcomes),
although these parameters are unlikely to vary
notably between GLP-1 receptor agonists and
inclusion of thee variables is unlikely to change
the conclusions of the analysis. While the use of
a network meta-analysis may be considered a
weakness, the conclusions of the network
meta-analysis are likely to be robust. Across
the phase 3 liraglutide trial program, both the
1.2 and 1.8 mg doses have consistently been
shown to be associated with reductions in
HbA1c of 1% or more and significant weight
loss [40]. The network meta-analysis found that
liraglutide 1.2 mg was associated with a larger
reduction in HbA1c than exenatide 10 lg BID
and lixisenatide 20 lg, which was statistically
significant in both cases.
An additional limitation may be that not all
treatments a patient with type 2 diabetes not
achieving glycemic control on metformin
monotherapy may receive were included in
the analysis. Additional therapy options
include sodium-glucose co-transporter type 2
(SGLT-2) inhibitors or weekly GLP-1 receptor
agonists. These therapy options were not
included in the cost-effectiveness analysis, as
the purpose of the network meta-analysis on
which it was based was to compare the clinical
efficacy of daily administered GLP-1 receptor
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agonists and it, therefore, did not contain data
for these interventions. Additional
cost-effectiveness analyses of other therapies
patients not achieving glycemic control on
metformin monotherapy may receive is
required to further inform decision making
and resource allocation.
A further limitation of the present analysis is
the reliance on short-term data in making
long-term predictions of outcomes over time
horizons of up to 50 years. However, this is a
limitation inherent to most cost-effectiveness
modeling studies and, despite this, such studies
represent one of the best available options for
making estimates of long-term clinical and
economic outcomes in the absence of
long-term clinical data. As a result there is
unavoidable uncertainty around how well the
modeling analysis represents the real world. The
present study aims to minimize this limitation,
through use of a recently validated model,
which has been accepted by a number of
reimbursement authorities, to conduct the
analysis and by conducting extensive
sensitivity analyses to examine the effects of
alternative inputs on long-term projections
[31].
CONCLUSIONS
The present study represents the first long-term
cost-effectiveness analysis of alternative daily
administered GLP-1 receptor agonists in the UK
setting. The analysis suggests that, based on
changes in clinical parameters from a network
meta-analysis, treatment with liraglutide 1.2 mg
was associated with improved life expectancy
and quality-adjusted life expectancy. These
improved clinical outcomes came at a cost
saving versus exenatide and lixisenatide.
Whilst liraglutide was associated with the
highest acquisition costs, this was entirely
offset by cost savings as a result of avoided
treatment of diabetes-related complications.
Liraglutide 1.2 mg once daily was projected to
be dominant over exenatide 10 lg BID and
lixisenatide 20 lg once daily for insulin naı¨ve
patients with type 2 in the UK setting.
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